On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

or full (5.0 mg) dose twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal recurrent venous thromboembolism, assessed in a noninferiority analysis (margin of ...

The anticlotting drug, Eliquis, has been approved for use in the United States by the country’s regulatory body, the Food and Drug Administration (FDA). Eliquis is manufactured by Bristol-Myers ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least ...